奥沙利铂联合氟尿嘧啶/亚叶酸钙肝动脉灌注与索拉非尼治疗晚期肝细胞癌的比较
本回顾性研究纳入2012年1月至2015年12月412例晚期肝细胞癌患者,其中232例接受索拉非尼治疗,180例接受奥沙利铂联合氟尿嘧啶/亚叶酸钙肝动脉灌注(HAIF)治疗。HAIF组中位无进展生存期(PFS)和中位总生存期(OS)均显著长于索拉非尼组,倾向性评分匹配后结果一致。作者认为HAIF可能改善晚期肝细胞癌患者生存,一项前瞻性随机试验正在进行以确认此发现。
要点
- HAIF组中位PFS为7.1个月(RECIST)/7.4个月(mRECIST),索拉非尼组为3.3个月(RECIST)/3.6个月(mRECIST),差异有统计学意义(P<0.001)。
- HAIF组中位OS为14.5个月,索拉非尼组为7.0个月,差异有统计学意义(P<0.001)。
- 多因素分析显示HAIF是PFS(HR 0.389 [RECIST]/0.402 [mRECIST],P<0.001)和OS(HR 0.129,P<0.001)的独立影响因素。
核心结论
- 作者认为,与索拉非尼相比,HAIF治疗可能改善晚期肝细胞癌患者的生存;一项前瞻性随机试验正在进行以确认此发现。
研究设计与样本
- 本回顾性研究经伦理审查委员会批准,所有患者治疗前均获得知情同意。
- 研究纳入2012年1月至2015年12月412例晚期肝细胞癌患者(376例男性,36例女性),中位年龄51岁(范围16-82岁)。
- 232例患者接受索拉非尼治疗,180例接受HAIF治疗;HAIF被推荐为拒绝索拉非尼患者的替代治疗选择。
- 采用倾向性评分匹配估计以减少生存评估中的偏倚,生存曲线采用Kaplan-Meier法计算,并用log-rank检验和Cox回归模型比较。
主要发现
- HAIF组中位PFS显著长于索拉非尼组(RECIST:7.1 vs. 3.3个月;mRECIST:7.4 vs. 3.6个月;P<0.001)。
- HAIF组中位OS显著长于索拉非尼组(14.5 vs. 7.0个月;P<0.001)。
- 在倾向性评分匹配队列(147对)中,HAIF组PFS和OS均长于索拉非尼组(P<0.001)。
- 多因素分析中,HAIF治疗是PFS(HR 0.389 [RECIST]/0.402 [mRECIST];P<0.001)和OS(HR 0.129;P<0.001)的独立影响因素。
临床怎么用
- 原文未据此给出推荐;作者在结论中认为HAIF治疗可能改善晚期肝细胞癌患者生存,并指出一项前瞻性随机试验正在进行以确认此发现。
局限性
- 原文未报告局限性;作者指出一项前瞻性随机试验正在进行以确认此发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: To compare the overall survival (OS) and disease progression free survival (PFS) in patients with advanced hepatocellular carcinoma (Ad-HCC) who are undergoing hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment vs. sorafenib. METHODS: This retrospective study was approved by the ethical review committee, and informed consent was obtained from all patients before treatment. HAI of FOLFOX (HAIF) was recommended as an alternative treatment option for patients who refused sorafenib. Of the 412 patients with Ad-HCC (376 men and 36 women) between Jan 2012 to Dec 2015, 232 patients were treated with sorafenib; 180 patients were given HAIF therapy. The median age was 51 years (range, 16-82 years). Propensity-score matched estimates were used to reduce bias when evaluating survival. Survival curves were calculated by performing the Kaplan-Meier method and compared by using the log-rank test and Cox regression models. RESULTS: The median PFS and OS in the HAIF group were significantly longer than those in the sorafenib group (PFS 7.1 vs. 3.3 months [RECIST]/7.4 vs. 3.6 months [mRECIST], respectively; OS 14.5 vs. 7.0 months; p <0.001 for each). In the propensity-score matched cohorts (147 pairs), both PFS and OS in the HAIF group were longer than those in the sorafenib group (p <0.001). At multivariate analysis, HAIF treatment was an independent factor for PFS (hazard ratio [HR] 0.389 [RECIST]/0.402 [mRECIST]; p <0.001 for each) and OS (HR 0.129; p <0.001). CONCLUSION: HAIF therapy may improve survival compared to sorafenib in patients with Ad-HCC. A prospective randomized trial is ongoing to confirm this finding. LAY SUMMARY: We compared the hepatic arterial infusion of FOLFOX (a combination chemotherapy) with sorafenib (a tyrosine kinase inhibitor) in patients with advanced hepatocellular carcinoma, retrospectively. It was found that hepatic arterial infusion of FOLFOX therapy may improve both progression free and overall survival in patients with advanced hepatocellular carcinoma.
引用
- Lyu N, Kong Y, Mu L, et al. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma. J Hepatol. 2018. PMID: 29471013. doi:10.1016/j.jhep.2018.02.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。